CVS Health is offering Hepatitis A vaccinations in Oahu following an import of frozen raw tuna that was positive for containing the virus. Read More »

Genentech's Phase III IMvigor211 clinical trial did not meet its primary endpoint of overall survival. Read More »

EMD Serono has received Food and Drug Administration approval of BAVENCIO (avelumab) as a treatment for locally advanced or metastatic urothelial carcinoma. Read More »

Teva Pharmaceutical Industries Ltd. will make a generic version of Vytorin (ezetimibe and simvastatin) available in America. Read More »

Imprimis Pharmaceutical Inc. launch its new Simple drops glaucoma drops at the American Society of Cataract and Refractive Surgery 2017 meeting at the Los Angeles Convention Center this month. Read More »

The American Society of Health-System Pharmacists has awarded 11 pharmacy students with both recognition and a cash reward for their excellence in their education, both on campus and pharmacy practice. Read More »

Novo Nordisk announced this month a new combo therapy for the treatment of diabetes. Read More »

CVs Health has earned #50 in the ranking for DiversityInc's 2017 Top 50 Companies for Diversity. This is the first time that CVS has been on the list, though it was #25 on the Noteworthy listing in the past. Read More »

Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal. Read More »

A major pharmacy benefit manager has announced a program to provide discounted drugs to uninsured Americans. Read More »

Pharmacy benefit managers should be praised for helping to keep down the cost of prescription drugs, rather than attacked by Congress and others, according to one health policy adviser. Read More »

Imprimis Pharmaceuticals Inc., and SightLife Surgical have signed a sales and marketing agreement in which SightLife will be offering Imprimis' autologous eye drops, Serum Tears, which have been specially formulated for patients suffering from chronic dry eye who require more than traditional treatment. Read More »

Celgene Corporation recently announced that the primary endpoint has been met for its Phase III Sunbeam trial, which evaluated the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS). Read More »

Sunovion Pharmaceuticals Inc., five leading mental health advocacy organizations and singer, songwriter and mental health advocate Demi Lovato recently released "Beyond Silence," a documentary about their experience with speaking out for mental health. Read More »

Kaiser Permanente has published research in JAMA Pediatrics that showcases the development of a neonatal sepsis risk calculator that has safely reduced antibiotic use by nearly 50 percent in newborns. Read More »

The U.S. Food and Drug Administration has accepted Pfizer's Biologics License Application for inotuzumab ozogamicin. Read More »

Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), has been accepted by the U.S. Food and Drug Administration. Read More »

AbbVie, a global biopharmaceutical company, recently announced its Viekirax + Exviera eight-week treatment program has been granted a positive opinion by the European Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »

Pfizer Inc. recently released top-line results for ORAL Strategy, a Phase 3B/4 study of XELJANZ (tofacitinib citrate) 5mg twice daily in the treatment of moderate to severe rheumatoid arthritis. Read More »

The European Commission has adopted a decision to change the Repatha (evolocumab) marketing authorization, approving a new single-dose delivery option. Read More »